EUVIMEDEUVIMED entdecken
Crossref

Inhibition studies to direct oral immunotherapy in walnut‐hazelnut co‐allergic patients (nut CRACKER study)

Yael Koren iD, Michael Y Appel iD, Matan Elkan iD, Liat Nachshon iD, Lars Mattsson iD, Jonas Lidholm iD, Michael B Levy, Arnon Elizur iD, Michael R Goldberg iD

Pediatric Allergy and Immunology · 2026-10 · 37 (10)

DOI: 10.1111/pai.70500 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Allergy and Immunology, online erschienen am 02.10.2026. Verfasst von Yael Koren und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Allergy, Immunology and Pediatric Pulmonology, Shamir (Assaf Harofeh) Medical Center, Be'er Ya'akov, Israel. Hauptthemen laut MEDLINE: Nut Hypersensitivity, Juglans, Corylus, Desensitization, Immunologic. Die Arbeit nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Walnut OIT has been observed to induce cross‐desensitization to hazelnut, but predictors of this response remain unclear. We sought to identify molecular predictors of hazelnut cross‐desensitization following walnut OIT, to help guide treatment decisions in these co‐allergic patients.

Methods

Patients with confirmed IgE‐mediated walnut and hazelnut allergy underwent walnut OIT. Patients achieving full walnut desensitization to 4 g of walnut protein were re‐challenged to 4‐grams hazelnut protein after 6 months. Baseline sera were obtained and competitive ELISA inhibition assays performed to evaluate serum IgE cross‐recognition of total walnut, total hazelnut and hazelnut component‐specific IgE. Results were compared between patients fully (4‐grams protein) or clinically (≥30‐fold ED increase or mild reaction at full dose) cross‐desensitized to hazelnut and those who remained hazelnut allergic following walnut OIT.

Results

Overall, 12/22 (54.5%) patients were fully cross‐desensitized and 14/22 (63.6%) patients were clinically cross‐desensitized to hazelnut following walnut OIT. Among the latter, walnut inhibited total hazelnut‐specific IgE binding by a median of 95%, compared to 55% in those who remained hazelnut allergic ( p < .01). Similarly, walnut extract competed for IgE binding to hazelnut components Cor a 9 ( p = .003) and Cor a 16 ( p = .023) in the cross‐desensitized group following walnut OIT, but not in the persistent hazelnut allergic group. A ≥70% inhibition threshold accurately predicted cross‐desensitization in 93% of cases ( p < .001).

Conclusion

Walnut OIT can induce clinical cross‐desensitization to hazelnut in >60% of co‐allergic individuals. Competitive ELISA inhibition is a promising predictive tool, with potential to guide targeted and efficient OIT strategies in walnut‐hazelnut co‐allergic patients. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Nut HypersensitivityJuglansCorylusDesensitization, ImmunologicAllergensHumansImmunoglobulin EFemaleMaleCross ReactionsChildAdolescentAdministration, OralAntigens, PlantEnzyme-Linked Immunosorbent Assay

Stichwörter der Autor:innen

ELISAcomponentsfood allergyoral immunotherapytree nut allergy

Substanzen

Immunoglobulin EAllergensAntigens, Plant

Autor:innen und Institutionen

  • Institute of Allergy, Immunology and Pediatric Pulmonology, Shamir (Assaf Harofeh) Medical Center, Be'er Ya'akov, Israel.
  • Department of Pediatrics, Shamir Medical Center, Zerifin, Israel, Affiliated to the Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Department of Medicine, Shamir Medical Center, Zerifin, Israel, Affiliated to the Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
  • Thermo Fisher Scientific, Uppsala, Sweden.

ORCID-Profile: Yael Koren, Michael Y Appel, Matan Elkan, Liat Nachshon, Lars Mattsson, Jonas Lidholm, Arnon Elizur, Michael R Goldberg

Zitieren

APA

Koren, Y., Appel, M. Y., Elkan, M., Nachshon, L., Mattsson, L., Lidholm, J., Levy, M. B., Elizur, A., & Goldberg, M. R. (2026). Inhibition studies to direct oral immunotherapy in walnut‐hazelnut co‐allergic patients (nut CRACKER study). Pediatric Allergy and Immunology, 37(10). https://doi.org/10.1111/pai.70500

Vancouver

Koren Y, Appel MY, Elkan M, Nachshon L, Mattsson L, Lidholm J, et al. Inhibition studies to direct oral immunotherapy in walnut‐hazelnut co‐allergic patients (nut CRACKER study). Pediatric Allergy and Immunology. 2026;37(10). doi:10.1111/pai.70500

BibTeX
@article{Koren2026,
  author = {Koren, Yael and Appel, Michael Y and Elkan, Matan and Nachshon, Liat and Mattsson, Lars and Lidholm, Jonas and Levy, Michael B and Elizur, Arnon and Goldberg, Michael R},
  title = {Inhibition studies to direct oral immunotherapy in walnut‐hazelnut co‐allergic patients (nut CRACKER study)},
  journal = {Pediatric Allergy and Immunology},
  year = {2026},
  volume = {37},
  number = {10},
  doi = {10.1111/pai.70500}
}
Kostenlos starten →